Passage Bio's core business segment revolves around the research, development, and clinical application of gene therapies targeting neurodegenerative diseases. This involves leveraging adeno-associated virus (AAV) vectors to deliver functional genes to the central nervous system, addressing the underlying genetic causes of these conditions. The company's R&D efforts focus on optimizing AAV capsid design for enhanced delivery and reduced immunogenicity. Clinical trials are conducted to evaluate the safety and efficacy of these therapies in patient populations with unmet medical needs. This segment aims to provide potentially curative treatments for debilitating neurological disorders, improving patient outcomes and quality of life. Future opportunities include expanding the pipeline to address a broader range of neurodegenerative conditions and exploring novel gene editing technologies.